View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
September 18, 2018updated 09 Aug 2019 8:16am

Will the UK relax its current regulations for cannabis-based products?

Recently medicinal cannabis has been at the forefront of media attention in the UK, and in July 2018 the UK home secretary announced that specialist doctors can legally prescribe cannabis-based products in the event of an exceptional clinical need.

Recently medicinal cannabis has been at the forefront of media attention in the UK, and in July 2018 the UK home secretary announced that specialist doctors can legally prescribe cannabis-based products in the event of an exceptional clinical need. This decision by the Home Office will place cannabidiol products into Schedule 2 of the Misuse of Drugs Regulations 2001, meaning it can be possessed lawfully by anyone who is given a prescription.

Could this radical change in policy potentially cause the UK to further relax its regulations, especially if medicinal cannabis proves efficacious and safe in other clinical trials?

Prior to this change in regulation, cannabis-derived products belonged to Schedule 1 of the Misuse of Drugs Regulations 2001, which meant there was no therapeutic value associated with the drug, so it could not be lawfully possessed or prescribed and could only be used solely for research purposes. In 2013, Bayer’s Sativex, approved for muscle spasticity, and was reclassified as Schedule 4 part 1 under the Misuse of Drugs Regulations, meaning patients can lawfully possess the drug under prescription, though non-prescribed possession would be an offence. However, there were no more reviews into the policy for other cannabis-derived products.

The drug at the centre of this recent radical policy change was GW Pharmaceuticals’ Epidiolex, which is indicated for Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS), both of which are rare forms of epilepsy. In a Phase III double-blind controlled study for LGS, 42.2% of patients who were given Epidiolex had a 50% reduction in the number of seizures, compared with 23.5% of patients who were given placebo. Furthermore, there were no differences in the number of patients who suffered from status epilepticus between those given Epidiolex compared with those who were administered placebo, which gave assurance for the safety profile of the drug. Similar results were achieved with Epidiolex’s Phase III trial for DS. Key opinion leaders (KOLs) interviewed by GlobalData also expressed that Epidiolex has the potential to help at least 50% of epileptic patients and it will be safe and well-tolerated.

With the clear progression of policy change surrounding medicinal cannabis, the UK government may be starting to recognise that cannabis can create a health benefit for patients suffering from neurological disorders. There are currently eight ongoing studies taking place in the UK that look at cannabidiol’s efficacy across a range of disorders, such as multiple sclerosis, infantile spasm, and graft-versus-host disease. If medicinal cannabis continues to boast a good efficacy and safety profile in these studies, it could lead to the relaxation of regulations and soften the stigma surrounding the drug.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena